A look at Pfizer
Pfizer’s (PFE) pharmaceutical product portfolio is classified into two business segments—its Innovative Health business and its Essential Health business. The chart below compares Pfizer’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.
Stock performance and recommendations
Pfizer’s (PFE) stock price has increased ~22.0% in the third quarter. Its stock price increased ~22.3% YTD (year-to-date) on October 2.
Wall Street analysts expect Pfizer’s stock price to fall ~3.8% over the next 12 months. Analysts’ recommendations show a 12-month target price of $42.61 per share, compared its October 1 price of $44.27 per share.
Nineteen analysts currently track Pfizer stock. One analyst recommends a “strong buy,” nine analysts recommend a “buy,” seven analysts recommend a “hold,” and two analysts recommend a “strong sell.” The consensus rating for Pfizer stands at 2.63, which represents a “hold.”
Analysts’ revenue estimates
Pfizer’s revenues are driven by pharmaceuticals products such as Eliquis, Lyrica, Ibrance, Xeljanz, and Xtandi, as well as growth in its alliance revenues.
Wall Street analysts expect Pfizer to report third-quarter EPS of $0.74 on revenues of $13.6 billion. This represents 3.2% revenue growth, compared to $13.2 billion reported in the third quarter of 2017.